PIONEER: avapritinib in patients with indolent systemic mastocytosis
0 Views
administrator
07/09/23
Cem Akin MD, PhD, of the University of Michigan, Ann Arbor, MI, discusses the results of PIONEER (NCT03731260), a randomized, double-blind, placebo-controlled, Phase II study of avapritinib in patients with indolent systemic mastocytosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
-
Category
Show more
Facebook Comments
No comments found